Action on Hearing Loss Logo
    Total results:
    Search
      Total results:

      A new treatment for Ménière’s disease in sight?

      Ménière’s disease causes severe dizziness and tinnitus and affects 1 in 1,000 people in the UK. Although it can be managed effectively, there is currently no cure. Nicola Robas, from our Biomedical Research team, tells us more about Ménière’s and about a clinical trial testing a new treatment.

      By: Nicola Robas | 11 March 2016

      The ear and balance

      The inner ear contains the sensory organs for hearing - the cochlea, and balance - the vestibular system (see picture).

      These organs consist of fluid-filled chambers containing cells that can detect movement. In the cochlea, sound waves passing through the fluids are detected by hair cells and converted into electrical signals which are sent to the brain and perceived as sound. In the vestibular system, the speed and direction of movement of the fluid is detected by a different type of sensory cell, which sends balance signals to the brain.

      Your brain uses the combined information from the vestibular system of each ear to understand the position of your head in three-dimensional space; and the direction and speed of movement of your body. This information is then used to control movements of the eye and the skeletal muscles so that adjustments can be made to keep the body balanced and orientated.

      These interacting brain signals occur very rapidly and, when the vestibular system is working properly, muscle adjustments are made continuously without us even thinking about it.  But, when the vestibular system is not working properly, these brain signals go out of sync, leading to symptoms such as dizziness and loss of balance.

      What is Ménière’s disease?

      Ménière’s disease is a condition of the inner ear that causes vertigo (severe dizziness), tinnitus, a feeling of fullness or congestion in the ear, and hearing loss.  The symptoms, caused by the build-up of fluid in the compartments of the inner ear, usually only affect one ear.

      The most dramatic effect of this fluid build-up is that it alters the signals from the vestibular system. As a result, the brain receives conflicting information from the affected and unaffected ear. This means it can’t determine the position of the head in space, leading to vertigo and loss of balance. Signals from the cochlea can also be altered, resulting in tinnitus and, in some cases, fluctuating hearing loss.

      Causes and treatments

      Research into the reasons behind the fluid build-up in Ménière’s disease is ongoing, but we don’t yet know the exact cause. There is some evidence that it could be due to changes in blood flow to the inner ear – or a consequence of viral infections, allergies, or autoimmune reactions. 7-10% of affected people have a family history of the condition so there may also be a genetic component. Ménière’s disease can develop at any age, but it is more likely to occur in adults aged between 40 and 60.

      There is no cure for Ménière’s disease, but there are ways to relieve and manage the symptoms. GPs may recommend reducing salt intake or prescribe a diuretic to reduce the fluid levels in your inner ear and salt levels in your body. Steroids can help – especially if your symptoms include a sudden decrease in hearing. In severe cases that do not respond to treatment, surgery may be required.

      A new steroid therapy?

      Steroids are thought to help treat the symptoms of Ménière’s disease by reducing inflammation caused by viral infections or allergic reactions. They may also play a role in regulating the levels of sodium and potassium in the fluids of the inner ear. Steroids can be given orally, but this can have unwanted side effects, especially if high doses are needed. To avoid these side effects, steroids can be given by injection through the eardrum directly into the middle ear. The disadvantage of this approach is that much of the steroid dose can be lost from the middle ear through the Eustachian tube and swallowed before it has a chance to diffuse into the inner ear.

      A new experimental medicine, OTO-104, aims to address this problem and is currently being tested in clinical trials, both here and in the USA. OTO-104 is a long-acting gel containing the steroid dexamethasone, which is injected through the eardrum into the middle ear where it slowly releases the steroid. In a previous clinical trial in the USA with a small group of Ménière’s disease patients, a single dose of OTO-104 was shown to be safe and well-tolerated – and appeared to reduce vertigo frequency, and improve the patients’ tinnitus symptoms.

      Now, a larger clinical study is investigating the safety of multiple doses of OTO-104, and its effectiveness compared to placebo (dummy) treatment in reducing the frequency of extreme vertigo. The UK part of the study is being conducted at several hospitals across the country: 125 people with Meniere's disease are needed to take part, for around 12 months.

      Rigorous clinical trials like these are essential to test whether an experimental medicine is safe and effective. If a new medicine successfully completes all the phases of clinical testing, health regulators, doctors, and the public can be confident that it is safe and proven to help the people who need it.

      More information

      More information about the OTO-104 clinical trial can be found at the trial website.
      More information about ways to manage Ménière’s disease can be found in our factsheet

      In 2011, Chris Packham talked to us about his Ménière’s disease

      Recent Posts

      The cuticular plate: the foundations of hearing

      Tiny sensory cells in the inner ear, called hair cells, are vital for our hearing. One particular part of the hair cell, the cuticular plate, has recently been the focus of research by a team at the University of Virginia School of Medicine. The structure was found to play an important role in hearing and it was discovered that defects in it may lead to hearing loss.

      By: Dr Marta Narkiewicz
      15 April 2019

      Identifying antibiotics that are less toxic to the ear

      We funded a consortium of researchers from universities and industry to identify antibiotics, which are less toxic to the ear, but that are still effective in fighting life-threatening bacterial infections. The results have now been published in the journal Scientific Reports. Our Translational Research Manager, Dr Carina Santos, tells us more about their work.

      By: Dr Carina Santos
      15 April 2019

      Stress-relieving products to make life easier

      To mark Stress Awareness Month, we’ve selected our top stress-relieving products for people with deafness, tinnitus and hearing loss. We’ve a practical solution for every situation, to reduce anxiety and give you, or a loved one, a renewed zest for life.

      By: Sally Bromham
      14 April 2019

      Kick starting new research

      Our Flexi grant helps researchers kick start new lines of research. We’re awarding funding to three new projects that could lead to new diagnostic tools, a gene therapy for a specific type of inherited deafness and pave the way for clinical trials of treatments to prevent hearing loss caused by the anti-cancer drug cisplatin. Our Executive Director of Research, Dr Ralph Holme, tells us more.

      By: Dr Ralph Holme
      11 April 2019

      Recent Posts

      The cuticular plate: the foundations of hearing

      Tiny sensory cells in the inner ear, called hair cells, are vital for our hearing. One particular part of the hair cell, the cuticular plate, has recently been the focus of research by a team at the University of Virginia School of Medicine. The structure was found to play an important role in hearing and it was discovered that defects in it may lead to hearing loss.

      By: Dr Marta Narkiewicz
      15 April 2019

      Identifying antibiotics that are less toxic to the ear

      We funded a consortium of researchers from universities and industry to identify antibiotics, which are less toxic to the ear, but that are still effective in fighting life-threatening bacterial infections. The results have now been published in the journal Scientific Reports. Our Translational Research Manager, Dr Carina Santos, tells us more about their work.

      By: Dr Carina Santos
      15 April 2019

      Stress-relieving products to make life easier

      To mark Stress Awareness Month, we’ve selected our top stress-relieving products for people with deafness, tinnitus and hearing loss. We’ve a practical solution for every situation, to reduce anxiety and give you, or a loved one, a renewed zest for life.

      By: Sally Bromham
      14 April 2019

      Kick starting new research

      Our Flexi grant helps researchers kick start new lines of research. We’re awarding funding to three new projects that could lead to new diagnostic tools, a gene therapy for a specific type of inherited deafness and pave the way for clinical trials of treatments to prevent hearing loss caused by the anti-cancer drug cisplatin. Our Executive Director of Research, Dr Ralph Holme, tells us more.

      By: Dr Ralph Holme
      11 April 2019

      More like this

      We're really proud of everyone who's a part of Action on Hearing Loss, and hope you'll feel inspired to become a part of our community.​

      We campaign for changes that make life better for people who are confronting deafness, tinnitus and hearing loss.

      Our ears are our organs of hearing and balance. They have three parts: the outer, middle and inner ear.